Baidu
map

Nature:清华学者发现转录因子Ascl2启动滤泡辅助T细胞(Tfh)的发育

2014-01-20 koo ebiotrade

日前,来自清华大学医学院、得克萨斯大学 MD 安德森癌症中心等机构的研究人员在《自然》(Nature)杂志上报告称,他们揭示出了转录因子 Ascl2 启动了滤泡辅助 T 细胞(follicular T-helper-cell, Tfh)发育。 T 淋巴细胞源自骨髓的多能干细胞。在胚胎期和初生期,骨髓中的一部分多能干细胞或前 T 细胞迁移到胸腺内,在胸腺激素的诱导下

Nature:清华董晨发表免疫学研究新成果


日前,来自清华大学医学院、得克萨斯大学 MD 安德森癌症中心等机构的研究人员在《自然》(Nature)杂志上报告称,他们揭示出了转录因子 Ascl2 启动了滤泡辅助 T 细胞(follicular T-helper-cell, Tfh)发育。【原文下载】

T 淋巴细胞源自骨髓的多能干细胞。在胚胎期和初生期,骨髓中的一部分多能干细胞或前 T 细胞迁移到胸腺内,在胸腺激素的诱导下分化成熟,成为具有免疫活性的 T 细胞。按照功能和表面标志物, T 细胞可以分成很多种类,包括细胞毒 T 细胞、调节/抑制 T 细胞,记忆 T 细胞和辅助 T 细胞。在免疫反应中,辅助 T 细胞扮演着中间过程的角色,它可以通过增生扩散来激活其他类型产生直接免疫反应的免疫细胞。

Tfh 细胞是近年来研究发现的一种特殊的辅助性 T 细胞。 Tfh 细胞最早在人扁桃体中发现,被描述为一类表达趋化因子受体 CXCR5 的CD4+ T 细胞,起初被发现定位于淋巴组织 B 细胞区。 Tfh 细胞特征性的标志为 CXCR5 +、PD-1+、ICOS+、 CCR7 -。同时,表达转录因子 Bcl-6。这些特征明显区别于其他Th亚群,使得 Tfh 被划分为 Th 细胞的一个新亚群。

Tfh 细胞在生发中心(germinal center,GC)形成和 B 细胞分化中起重要作用。 Tfh 细胞参与了机体免疫,对维持机体免疫平衡起重要作用。 Tfh 细胞功能失调与例如自身免疫性疾病、免疫缺陷和肿瘤等许多疾病有一定的关系。因此,机体内存在一系列复杂的调控机制,以保证 Tfh 细胞的正常发育、分化和功能。但目前对于这些调控机制仍然不是很清楚。

在这项最新研究中,科学家发现一种 bHLH(basic Helix- Loop-Helix, 碱性螺旋-环-螺旋)转录因子: Ascl2 (achaete-scute homologue 2)在 Tfh 细胞中选择性的表达上调。在体外实验中他们证实异位表达 Ascl2 上调了 T 细胞中的 CXCR5 的表达,下调了 CCR7 表达,而Bcl6则不受影响。在体内实验中他们证实异位表达 Ascl2 可加速 T 细胞迁移到滤泡及 Tfh 细胞发育。

全基因组分析结果表明, Ascl2 直接调控了 Tfh 细胞相关的基因,而抑制了 TH1 细胞和 TH17 细胞标记基因表达。在 CD4+ T 细胞中敲除 Ascl2 以及采用 Id3 蛋白阻断 Ascl2 的功能,可损害 Tfh 细胞发育及生发中心反应。相反,Id3 突变则可显著增进 Tfh 细胞生成。

这些结果表明, Ascl2 直接启动了 Tfh 细胞发育。新研究为深入了解 Tfh 发育机制以及在机体免疫和相关疾病中的作用提供了重要的研究数据。

领导这一研究的是现任职清华大学医学院和 MD 安德森癌症中心的董晨(Chen Dong)教授。董教授是全球免疫学界最顶尖的学者之一。其领导的团队在发现重要免疫耐受调节分子方面做出了重要贡献。2009 年被美国免疫学学会授予取得杰出成就的青年免疫学家奖,已在国际一流学术期刊发表论文及专著 100 多篇。

原文出处:
Xindong Liu, Xin Chen, Bo Zhong, Aibo Wang, Xiaohu Wang, Fuliang Chu, Roza I. Nurieva, Xiaowei Yan, Ping Chen, Laurens G. van der Flier, Hiroko Nakatsukasa, Sattva S. Neelapu, Wanjun Chen, Hans Clevers, Qiang Tian, Hai Qi, Lai Wei & Chen Dong. Transcription factor achaete-scute homologue 2 initiates follicular T-helper-cell development. Nature, 19 January 2014; doi:10.1038/nature12910 【原文下载】

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1972087, encodeId=167319e2087da, content=<a href='/topic/show?id=255b93668e8' target=_blank style='color:#2F92EE;'>#辅助T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93668, encryptionId=255b93668e8, topicName=辅助T细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed May 14 06:11:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879877, encodeId=5a3a18e987763, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 18 20:11:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938267, encodeId=58bb193826ed4, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Apr 01 08:11:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747177, encodeId=667f1e47177c8, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Dec 24 00:11:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347010, encodeId=fe75134e01079, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500056, encodeId=c0811500056f1, content=<a href='/topic/show?id=9e6866216d7' target=_blank style='color:#2F92EE;'>#清华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66216, encryptionId=9e6866216d7, topicName=清华)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29422809, createdName=医生2397, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537446, encodeId=d1e6153e44658, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1972087, encodeId=167319e2087da, content=<a href='/topic/show?id=255b93668e8' target=_blank style='color:#2F92EE;'>#辅助T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93668, encryptionId=255b93668e8, topicName=辅助T细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed May 14 06:11:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879877, encodeId=5a3a18e987763, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 18 20:11:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938267, encodeId=58bb193826ed4, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Apr 01 08:11:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747177, encodeId=667f1e47177c8, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Dec 24 00:11:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347010, encodeId=fe75134e01079, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500056, encodeId=c0811500056f1, content=<a href='/topic/show?id=9e6866216d7' target=_blank style='color:#2F92EE;'>#清华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66216, encryptionId=9e6866216d7, topicName=清华)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29422809, createdName=医生2397, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537446, encodeId=d1e6153e44658, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=)]
    2014-09-18 liye789132251
  3. [GetPortalCommentsPageByObjectIdResponse(id=1972087, encodeId=167319e2087da, content=<a href='/topic/show?id=255b93668e8' target=_blank style='color:#2F92EE;'>#辅助T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93668, encryptionId=255b93668e8, topicName=辅助T细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed May 14 06:11:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879877, encodeId=5a3a18e987763, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 18 20:11:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938267, encodeId=58bb193826ed4, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Apr 01 08:11:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747177, encodeId=667f1e47177c8, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Dec 24 00:11:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347010, encodeId=fe75134e01079, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500056, encodeId=c0811500056f1, content=<a href='/topic/show?id=9e6866216d7' target=_blank style='color:#2F92EE;'>#清华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66216, encryptionId=9e6866216d7, topicName=清华)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29422809, createdName=医生2397, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537446, encodeId=d1e6153e44658, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=)]
    2014-04-01 一叶知秋
  4. [GetPortalCommentsPageByObjectIdResponse(id=1972087, encodeId=167319e2087da, content=<a href='/topic/show?id=255b93668e8' target=_blank style='color:#2F92EE;'>#辅助T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93668, encryptionId=255b93668e8, topicName=辅助T细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed May 14 06:11:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879877, encodeId=5a3a18e987763, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 18 20:11:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938267, encodeId=58bb193826ed4, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Apr 01 08:11:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747177, encodeId=667f1e47177c8, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Dec 24 00:11:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347010, encodeId=fe75134e01079, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500056, encodeId=c0811500056f1, content=<a href='/topic/show?id=9e6866216d7' target=_blank style='color:#2F92EE;'>#清华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66216, encryptionId=9e6866216d7, topicName=清华)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29422809, createdName=医生2397, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537446, encodeId=d1e6153e44658, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=)]
    2014-12-24 mjldent
  5. [GetPortalCommentsPageByObjectIdResponse(id=1972087, encodeId=167319e2087da, content=<a href='/topic/show?id=255b93668e8' target=_blank style='color:#2F92EE;'>#辅助T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93668, encryptionId=255b93668e8, topicName=辅助T细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed May 14 06:11:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879877, encodeId=5a3a18e987763, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 18 20:11:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938267, encodeId=58bb193826ed4, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Apr 01 08:11:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747177, encodeId=667f1e47177c8, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Dec 24 00:11:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347010, encodeId=fe75134e01079, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500056, encodeId=c0811500056f1, content=<a href='/topic/show?id=9e6866216d7' target=_blank style='color:#2F92EE;'>#清华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66216, encryptionId=9e6866216d7, topicName=清华)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29422809, createdName=医生2397, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537446, encodeId=d1e6153e44658, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=)]
    2014-01-22 neurowu
  6. [GetPortalCommentsPageByObjectIdResponse(id=1972087, encodeId=167319e2087da, content=<a href='/topic/show?id=255b93668e8' target=_blank style='color:#2F92EE;'>#辅助T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93668, encryptionId=255b93668e8, topicName=辅助T细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed May 14 06:11:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879877, encodeId=5a3a18e987763, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 18 20:11:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938267, encodeId=58bb193826ed4, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Apr 01 08:11:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747177, encodeId=667f1e47177c8, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Dec 24 00:11:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347010, encodeId=fe75134e01079, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500056, encodeId=c0811500056f1, content=<a href='/topic/show?id=9e6866216d7' target=_blank style='color:#2F92EE;'>#清华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66216, encryptionId=9e6866216d7, topicName=清华)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29422809, createdName=医生2397, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537446, encodeId=d1e6153e44658, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=)]
    2014-01-22 医生2397
  7. [GetPortalCommentsPageByObjectIdResponse(id=1972087, encodeId=167319e2087da, content=<a href='/topic/show?id=255b93668e8' target=_blank style='color:#2F92EE;'>#辅助T细胞#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=78, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93668, encryptionId=255b93668e8, topicName=辅助T细胞)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0bed488, createdName=jktdtl, createdTime=Wed May 14 06:11:00 CST 2014, time=2014-05-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1879877, encodeId=5a3a18e987763, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu Sep 18 20:11:00 CST 2014, time=2014-09-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1938267, encodeId=58bb193826ed4, content=<a href='/topic/show?id=1c292818fd' target=_blank style='color:#2F92EE;'>#ASC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=71, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2818, encryptionId=1c292818fd, topicName=ASC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Tue Apr 01 08:11:00 CST 2014, time=2014-04-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1747177, encodeId=667f1e47177c8, content=<a href='/topic/show?id=832e93345c3' target=_blank style='color:#2F92EE;'>#转录#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93345, encryptionId=832e93345c3, topicName=转录)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=58df35929710, createdName=mjldent, createdTime=Wed Dec 24 00:11:00 CST 2014, time=2014-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1347010, encodeId=fe75134e01079, content=<a href='/topic/show?id=88713e938c1' target=_blank style='color:#2F92EE;'>#发育#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=62, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37938, encryptionId=88713e938c1, topicName=发育)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=f4c124, createdName=neurowu, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1500056, encodeId=c0811500056f1, content=<a href='/topic/show?id=9e6866216d7' target=_blank style='color:#2F92EE;'>#清华#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=66216, encryptionId=9e6866216d7, topicName=清华)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=10f29422809, createdName=医生2397, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1537446, encodeId=d1e6153e44658, content=<a href='/topic/show?id=798a93348bb' target=_blank style='color:#2F92EE;'>#转录因子#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93348, encryptionId=798a93348bb, topicName=转录因子)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b8c712868269, createdName=lanyan20020090, createdTime=Wed Jan 22 08:11:00 CST 2014, time=2014-01-22, status=1, ipAttribution=)]

相关资讯

JID:出生时接种卡介苗可诱导更强的T细胞反应

卡介苗(BCG)是唯一一个获许可的儿童结核病疫苗。卡介苗能够保护婴儿结核疾病相关严重疾病(结核脑膜炎和粟粒型结核)的发生,对降低婴儿发病率和死亡率有积极的作用。因此,在结核分枝杆菌接触风险高的地区,世界卫生组织推荐婴儿出生后就接种BCG疫苗。【原文下载】结核病在乌干达地区呈区域性流行,婴儿于出生后24小时内在卫生医疗机构常规接种BCG。然而,超过一半的婴儿都在家分娩,他们通常在6周龄首次去医疗机构

J Infect Dis:早期治疗HIV可有效降低T细胞活化水平和病毒载量

  治疗早期和晚期组的T细胞活化比较 抗逆转录病毒治疗介导的病毒抑制可降低CD4+和CD8+T细胞的活化水平,但患者持续的T细胞活化水平要高于HIV阴性对照组,这就意味着抗逆转录病毒治疗只是降低并没有颠覆HIV相关的免疫活化。为了解HIV感染早期的抗逆转录病毒治疗降低免疫活化的程度是否比慢性HIV感染接受治疗的患者更显著,以及早期治疗是否能够限制病毒载量,来自美国加利福尼亚大学Vivek&nbs

Immunocore公司:用自身T细胞杀死癌细胞

癌症一直是人类的梦魇,攻克癌症也成为无数科学家和医学人士殚精竭虑、孜孜以求的“圣杯”。各种抗癌方法层出不穷,但大多都在癌症强大的防御面前溃不成军。不过,这种情况有望获得改善。 现在,英国科学家另辟蹊径,提出了一种抗癌新方法:使用人体血液内的 T 细胞来杀死恶性肿瘤。这一技术目前还处于临床试验的第一阶段,结果如何?可能需要 5 年到 10 年时间,答案才能揭晓。 另辟蹊径: T 细胞杀死癌细胞

Nat Biotechnol:利用干细胞技术大量制造T细胞

在一项新的研究中,来自美国斯隆-凯特琳癌症纪念中心的研究人员利用干细胞技术开发出一种大量制造T细胞的方法;首先收集从体内分离出的T细胞,将它们重编程为诱导性多能干细胞,导入一种基因标记,接着再让这些干细胞变回能够靶向恶性肿瘤细胞的T细胞。相关研究结果于2013年8月11日在线发表在Nature Biotechnology期刊上,论文标题为“Generation of 

JCO:标准化疗可改善部分复发或难治性PTCL患者结局

研究结论:多数复发或难治性PTCL患者临床结果差,生存期短,选择体能状态好的患者给予标准化疗结果较好。 目前针对复发或难治性外周T细胞淋巴瘤(PTCL) 有大量处于研究阶段的新型治疗方法;然而,这些方法对患者结局的相对影响尚不明确。为此中国香港玛格丽特公主医院Vivien Mak等人进行了研究,该研究针对出现复发或进展且未进行造血干细胞移植的PTCL患者进行了研究,并

Nat Med:增进免疫系统功能有助抗癌

日前,来自美国费城儿童医院等机构的研究人员发现,一种通过增强人体免疫系统而后有助克癌的新方法。研究显示,至少一种肺癌细胞在调节T细胞攻击下受到遏制。新治疗方法可以保持微妙平衡,使得人体免疫系统在攻击癌细胞同时却不去攻击人体自身健康器官和组织。 动物实验结果已经显示这种通过调整免疫系统的方法可能会最终导致癌症新疗法的推出。研究发现成果已经在《自然-医学》杂志刊登。【原文下载】

Baidu
map
Baidu
map
Baidu
map